Senior Associate
CurrentSelected investments: SoluTx (Seed), Latus Bio (Series A), Auron (Series A), Umoja (Series B), Avicenna (Seed), Totus Medicine (Series B), Plexium (Series B), Novome (Series B), Cellanome (Series A, A2), Syntax (Seed), Stemson (Series A), CH4 Global (Series A).Due diligence, portfolio management, sourcing, landscape research. - Financial and deep technical diligence on 2 dozen companies.- Operational support to 3 in-house incubations. Attending BoD as an unofficial Board Observer for 5 portcos. Providing portcos with operational and strategic assistance, fundraising support.- Sourced an average of 1,000 companies/year from personal network, conferences, accelerators.- Deep dive research on Allogeneic Cell Therapy, Bispecific Antibodies, Autoimmune Diseases, Neurodegenerative, Psychedelic Medicines, Drug Delivery of Genetic Medicines, AI/ML in Drug Discovery, RNA Medicines.DCVC Bio is an SF-based early-stage venture capital firm investing in companies at the intersection of computation and life science. Our focus is on therapeutics, synthetic biology, industrial biotech, and agricultural tech, with a particular interest in companies developing revolutionary machine learning-powered platforms. Currently investing out of a $600M fund (Core + Opp).
